Advertisement
Organisation › Details
Pharvaris B.V.
Pharvaris (Nasdaq: PHVS) is a clinical-stage biopharmaceutical company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. Pharvaris brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. *
Start | 2016-04-07 existent | |
End | 2021-02-04 reorganised | |
Today | Pharvaris N.V. (Nasdaq: PHVS) | |
Successor | Pharvaris N.V. (Nasdaq: PHVS) | |
Industry | pharmaceutical | |
Industry 2 | PHA121 (incl in soft capsules as PHVS416) (Pharvaris) | |
Person | Modig, Berndt (Pharvaris CEO before Prosensa 201003 CFO before Jerini 200310– CFO before Surplex AG) | |
Region | Netherlands_oo | |
Country | Netherlands | |
Street | 21 J.H. Oortweg | |
City | 2333 CH Leiden | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Pharvaris N.V.. (2/4/21). "Press Release: Pharvaris Announces Pricing of Upsized Initial Public Offering". Zug. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Pharvaris B.V.
- [1] Pharvaris N.V.. (2/4/21). "Press Release: Pharvaris Announces Pricing of Upsized Initial Public Offering". Zug....
- [2] Pharvaris B.V.. (11/18/20). "Press Release: Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE". Zug....
- [3] Pharvaris B.V.. (9/10/19). "Press Release: Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema". Leiden....
- [4] Centogene AG. (5/4/18). "Press Release: Centogene Appoints Berndt Modig as New Supervisory Board Member". Rostock....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top